So many blind spots right out in the open…
Posted: Mon Nov 18, 2019 7:16 pm
I haven’t had much to say over the last several months because progress is apparent to me and continues to be articulated well by those intellectuals and medically vested among us. I have a little time here so decided to needlessly ramble on regarding the naysayers propensity to continually slander the success of Imetelstat’s future Even while, JS/Geron continue to expand their footprint, presence and strategy with financing, leadership and staff, CTs, KOL involvement, regulator designations and an accelerated information loop, etc. So what is not understood or missing?
In little more than one year, the seeds have all been pretty much planted to grow Geron into a mean, lean pharma machine in parallel with the coming acceptance of the first in class Imetelstat science and drug. They have expanded beyond basic oversight leadership to boots on the ground to take Imetelstat through various CT’s, regulatory approvals, manufacturing, delivery and marketing and into the strategic arena of combinations. So what is not understood or missing?
The costs will continue to increase, probably on a timely and occasionally in a ‘just in time’ manner as infrastructure is grown to match potential and opportunity. Surprises will likely abound. JS is conservative and not prone to intentionally mislead, giving me the confidence to believe we are on a very successful track. While over time we might feel that JS has intentionally undersold to the investors, but for me it’s for reasons we should all understand and appreciate by now. However, at this juncture, I feel like we should also be able to fill in some of the blanks given what we know. And, like me, for an old guy, I don’t think one should underestimate the amount of JS’s testosterone or his willingness to take the calculated risk to seize the opportunity in front of him. Seems to me, he is doing quite well on that measure. And as we all know, there is a lot of information and “intelligence” being exchanged in the pharma business at large between KOLs, business leaders and BODs that we are not privy to until made public. Personally, I like it that way so we all don’t feel the need to boil it down all the time. So what is not understood here or missing?
I don’t think there is anything out in a CT phase that is competitive with Imetelstat, then again I am a novice, just haven’t heard of anything or didn’t understand something or its progress in the ‘pipeline’. What I have been hearing about though, is a number of companies buying or licensing other treatments in the hemo space that are usually, in my opinion, second rate and/or palliative in nature. Why might the BPs be doing that? It seems a little strange to me but might it just be they want to keep expanding their footprint in treating hemo diseases and one clear option is that they are preparing for Imetelstat’s approval and eventual array of combinations. Since Imetelstat is not currently for sale, potentially they are looking for a way to share/profit in the coming onslaught of combinations with Imetelstat. So what is still missing here?
The ATM sales might not make sense to me but are occurring for reasons which make sense to JS and company. So what are the reasons? One reality is JS is not going to be beholden to any entity to bring Imetelstat to market. Actually that is what he has indicated in so many words. But could there be more, maybe much more? I think the 1Q2020 meeting with the FDA re: MF and the aggressive setup of Imetelstat inventory and manufacturing capability point to something much more significant. I think the aggressive addition of senior leadership and staff point to something much more significant. Of course with that come more expenses and salaries to pay as the staff increases, but what the additional staff is up to is probably just as or more expensive and far more important. The FPD in MF received in September plays a role in this and is ‘another signal’ along with the MDS progression that JS/Geron are stepping up their game as does the preclinical using Jakafi. Yes I have some grasp of the regulatory environment and BOD’s fiduciary duties, so given our current state of activity and progress, do we still need to continually second guess why the ATM sales? Until commercialization and associated revenue and profits, the ATM appears to be the funding vehicle of choice and I think JS/COB believe they are choosing the most effective course of action and we have to live with that question or not if you think there is something missing or hidden.
Compared to the last twenty years or so, this story is coming like a freight train running on an exponential track uphill. Seems to me much is rapidly coming together for patients, investors and Geron. So what is not understood or missing? While much is still hidden as it should be, for those of us who have been at this for a while at least for me, the writing on the wall can help us figure this one out and I don’t expect I will be disappointed.
Well of course, we still have to put up with the noise for a while that we have an old tired CEO and COB who are robbing us all blind. I for one am not going anywhere and greatly appreciate the solid thinking that ImetelChat provides. Which provides timely and quality information and logic (positives and negatives) in this space that is unblemished by obvious bashing as in the other boards.
In little more than one year, the seeds have all been pretty much planted to grow Geron into a mean, lean pharma machine in parallel with the coming acceptance of the first in class Imetelstat science and drug. They have expanded beyond basic oversight leadership to boots on the ground to take Imetelstat through various CT’s, regulatory approvals, manufacturing, delivery and marketing and into the strategic arena of combinations. So what is not understood or missing?
The costs will continue to increase, probably on a timely and occasionally in a ‘just in time’ manner as infrastructure is grown to match potential and opportunity. Surprises will likely abound. JS is conservative and not prone to intentionally mislead, giving me the confidence to believe we are on a very successful track. While over time we might feel that JS has intentionally undersold to the investors, but for me it’s for reasons we should all understand and appreciate by now. However, at this juncture, I feel like we should also be able to fill in some of the blanks given what we know. And, like me, for an old guy, I don’t think one should underestimate the amount of JS’s testosterone or his willingness to take the calculated risk to seize the opportunity in front of him. Seems to me, he is doing quite well on that measure. And as we all know, there is a lot of information and “intelligence” being exchanged in the pharma business at large between KOLs, business leaders and BODs that we are not privy to until made public. Personally, I like it that way so we all don’t feel the need to boil it down all the time. So what is not understood here or missing?
I don’t think there is anything out in a CT phase that is competitive with Imetelstat, then again I am a novice, just haven’t heard of anything or didn’t understand something or its progress in the ‘pipeline’. What I have been hearing about though, is a number of companies buying or licensing other treatments in the hemo space that are usually, in my opinion, second rate and/or palliative in nature. Why might the BPs be doing that? It seems a little strange to me but might it just be they want to keep expanding their footprint in treating hemo diseases and one clear option is that they are preparing for Imetelstat’s approval and eventual array of combinations. Since Imetelstat is not currently for sale, potentially they are looking for a way to share/profit in the coming onslaught of combinations with Imetelstat. So what is still missing here?
The ATM sales might not make sense to me but are occurring for reasons which make sense to JS and company. So what are the reasons? One reality is JS is not going to be beholden to any entity to bring Imetelstat to market. Actually that is what he has indicated in so many words. But could there be more, maybe much more? I think the 1Q2020 meeting with the FDA re: MF and the aggressive setup of Imetelstat inventory and manufacturing capability point to something much more significant. I think the aggressive addition of senior leadership and staff point to something much more significant. Of course with that come more expenses and salaries to pay as the staff increases, but what the additional staff is up to is probably just as or more expensive and far more important. The FPD in MF received in September plays a role in this and is ‘another signal’ along with the MDS progression that JS/Geron are stepping up their game as does the preclinical using Jakafi. Yes I have some grasp of the regulatory environment and BOD’s fiduciary duties, so given our current state of activity and progress, do we still need to continually second guess why the ATM sales? Until commercialization and associated revenue and profits, the ATM appears to be the funding vehicle of choice and I think JS/COB believe they are choosing the most effective course of action and we have to live with that question or not if you think there is something missing or hidden.
Compared to the last twenty years or so, this story is coming like a freight train running on an exponential track uphill. Seems to me much is rapidly coming together for patients, investors and Geron. So what is not understood or missing? While much is still hidden as it should be, for those of us who have been at this for a while at least for me, the writing on the wall can help us figure this one out and I don’t expect I will be disappointed.
Well of course, we still have to put up with the noise for a while that we have an old tired CEO and COB who are robbing us all blind. I for one am not going anywhere and greatly appreciate the solid thinking that ImetelChat provides. Which provides timely and quality information and logic (positives and negatives) in this space that is unblemished by obvious bashing as in the other boards.